Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta

30-Nov-2010

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain (DPNP).

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance